Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
35 studies found for:    M12-950
Show Display Options
Download search resultsDownload the search results for:
M12-950 (35 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Enrolling by invitation A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
Condition: Locally Advanced Rectal Cancer
Interventions: Drug: veliparib;   Drug: capecitabine;   Radiation: radiation
2 Recruiting Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
Interventions: Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
3 Completed Efficacy of a 12-week Regimen of Telaprevir, Peginterferon, and Ribavirin in Subjects With Interleukin-28B (IL28B) CC Genotype in Treatment-naive and Prior Relapser Subjects
Condition: Hepatitis C, Chronic
Interventions: Drug: telaprevir;   Drug: Peginterferon alfa-2a;   Drug: ribavirin
4 Active, not recruiting Phase I/II Thymus Transplantation With Immunosuppression #950
Conditions: DiGeorge Anomaly;   Complete DiGeorge Anomaly;   Complete Atypical DiGeorge Anomaly;   Complete DiGeorge Syndrome;   Complete Atypical DiGeorge Syndrome
Interventions: Biological: Thymus Tissue for Transplantation;   Other: Thymus Tissue and Parental Parathyroid Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Daclizumab;   Drug: Mycophenolate mofetil
5 Completed
Has Results
Evaluation of Prucalopride in Male Subjects With Chronic Constipation.
Condition: Male Subjects With Chronic Constipation
Interventions: Drug: placebo;   Drug: prucalopride
6 Terminated Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Conditions: Adenocarcinoma of the Pancreas;   Advanced Solid Tumors;   Cancer;   Cancer of Pancreas;   Cancer of the Pancreas;   Metastases;   Metastatic Cancer;   Metastatic Pancreatic Cancer;   Pancreas Cancer;   Pancreatic Cancer;   Bone Metastases;   Endocrine Cancer;   Oncology;   Oncology Patients;   Solid Tumors;   Advanced Malignancy
Interventions: Drug: AMG 479;   Drug: Placebo;   Drug: gemcitabine
7 Completed
Has Results
Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)
Condition: Overactive Bladder
Interventions: Drug: fesoterodine fumarate;   Drug: placebo;   Drug: tolterodine tartrate
8 Completed An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Condition: Chronic Hepatitis C Virus (HCV) Infection
Interventions: Drug: Telaprevir;   Drug: Pegylated interferon alfa-2a;   Drug: Ribavirin
9 Active, not recruiting Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: glioblastoma multiforme multipeptide vaccine IMA950;   Biological: sargramostim;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: adjuvant therapy;   Radiation: radiation therapy
10 Completed
Has Results
Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer
Condition: Neoplasms, Breast
Interventions: Drug: lapatinib;   Other: placebo
11 Completed Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Condition: Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions: Drug: Immune Globulin Intravenous (Human), 10% Caprylate/Chromatography Purified;   Drug: Albumin (Human) 25%, USP
12 Recruiting Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: CP-690,550
13 Recruiting AMG 181 Phase 2 Study in Subjects With Moderate to Severe Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Biological: AMG 181;   Other: Placebo
14 Terminated
Has Results
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Condition: Chronic Myeloid Leukemia
Interventions: Drug: ponatinib;   Drug: imatinib (Gleevec/ Glivec)
15 Recruiting A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis
Condition: Ulcerative Colitis
Interventions: Drug: Placebo;   Drug: CP690,550;   Drug: CP-690,550
16 Completed MICHELANGELO OASIS-6 : Fondaparinux in ST Elevation Myocardial Infarction
Conditions: Myocardial Infarction;   ST-elevation Myocardial Infarction;   Acute Coronary Syndrome;   Acute Myocardial Infarction
Interventions: Drug: Fondaparinux - UFH indicated;   Other: Control - UFH not indicated;   Drug: fondaparinux - UFH not indicated;   Drug: Control - UFH
17 Recruiting Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Fluticasone Furoate/Vilanterol;   Drug: Vilanterol
18 Completed
Has Results
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Conditions: Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa;   Drug: Placebo
19 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
20 Recruiting ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Condition: Acute Coronary Syndrome
Interventions: Drug: alirocumab SAR236553 (REGN727);   Other: placebo

   Previous Page Studies Shown (1-20) Next Page (21-35) Show next page of results    Last Page
Indicates status has not been verified in more than two years